These results are consistent with our present findings and suggest that pharmacological targeting of IGF-1R should be explored for the treatment/prevention of both the cognitive decline that accompanies aging and the neuropathology that characterizes late-onset AD. This evidence concerns the gene IGF1R and Alzheimer disease.